Verastem logo

Verastem Share Price (NASDAQ: VSTM)

$9.24

0.01

(0.11%)

Last updated on

Check the interactive Verastem Stock chart to analyse performance

Verastem stock performance

as on September 2, 2025 at 11:42 pm IST

  • Today's Low:$9.00
    Today's High:$9.32

    Day's Volatility :3.43%

  • 52 Weeks Low:$2.34
    52 Weeks High:$9.43

    52 Weeks Volatility :75.17%

Verastem Stock Returns

PeriodVerastem, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
56.78%
3.5%
0.0%
6 Months
56.78%
-7.7%
0.0%
1 Year
282.23%
-12.6%
0.0%
3 Years
704.35%
10.0%
-2.3%

Verastem, Inc. Key Stats

Check Verastem key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$9.25
Open
$9.29
Today's High
$9.52
Today's Low
$9.09
Market Capitalization
$569.3M
Today's Volume
$1.5M
52 Week High
$9.425
52 Week Low
$2.34
Revenue TTM
$2.1M
EBITDA
$-156.4M
Earnings Per Share (EPS)
$-3.5
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-437.92%

Stock Returns calculator for Verastem Stock including INR - Dollar returns

The Verastem stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Verastem investment value today

Current value as on today

₹3,86,844

Returns

₹2,86,844

(+286.84%)

Returns from Verastem Stock

₹2,81,818 (+281.82%)

Dollar Returns*

₹5,026 (+5.03%)

Indian investors sentiment towards Verastem Stock

7%

Period: Aug 2, 2025 to Sep 1, 2025. Change in 30 Days versus previous period

Search interest for Verastem Stock from India on INDmoney has increased by 7% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Verastem, Inc.

  • Name

    Holdings %

  • Balyasny Asset Management LLC

    7.78%

  • RTW INVESTMENTS, LLC

    6.91%

  • Vanguard Group Inc

    5.56%

  • Bvf Inc

    5.53%

  • Nantahala Capital Management, LLC

    4.80%

  • Orbimed Advisors, LLC

    4.65%

Analyst Recommendation on Verastem Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Verastem(by analysts ranked 0 to 5 stars)

Verastem Share Price Target

What analysts predicted

Upside of 67.75%

Target:

$15.50

Current:

$9.24

Verastem share price target is $15.50, a slight Upside of 67.75% compared to current price of $9.24 as per analysts' prediction.

Verastem Stock Insights

  • Price Movement

    In the last 1 month, VSTM stock has moved up by 52.1%

Verastem Technicals Summary

Sell

Neutral

Buy

Verastem is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Verastem, Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Verastem, Inc. logo
53.91%
56.78%
282.23%
704.35%
690.6%
Regeneron Pharmaceuticals, Inc. logo
1.6%
-14.03%
-50.32%
1.17%
0.57%
Beone Medicines Ltd logo
0.58%
18.94%
62.57%
87.24%
31.49%
Vertex Pharmaceuticals Incorporated logo
-17.2%
-19.58%
-17.8%
40.06%
46.22%
Alnylam Pharmaceuticals, Inc. logo
6.42%
83.8%
75.94%
121.86%
256.67%

About Verastem, Inc.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Organization
Verastem
Employees
78
CEO
Mr. Daniel W. Paterson
Industry
Health Technology

Key Management of Verastem, Inc.

NameTitle
Mr. Daniel W. Paterson
President, CEO & Director
Mr. Daniel Calkins
Chief Financial Officer
Dr. Robert A. Weinberg Ph.D.
Co-Founder & Chair of Scientific Advisory Board
Dr. Michelle Detwiler M.D., Ph.D.
Co-Founder
Mr. Matthew E. Ros
Chief Operating Officer
Dr. Jonathan Pachter Ph.D.
Chief Scientific Officer
Ms. Julissa Viana
Vice President of Corporate Communications & Investor Relations
Ms. Cathy Carew
Chief Organizational Effectiveness Officer
Mr. Nate Sanburn
Chief Business Officer
Mr. Michael Crowther
Chief Commercial & Strategy Officer

Important FAQs about investing in VSTM Stock from India :

What is Verastem share price today?

Verastem share price today is $9.24 as on at the close of the market. Verastem share today touched a day high of $9.32 and a low of $9.00.

What is the 52 week high and 52 week low for Verastem share?

Verastem share touched a 52 week high of $9.43 and a 52 week low of $2.34. Verastem stock price today i.e. is closed at $9.24, lower by 1.96% versus the 52 week high.

How to invest in Verastem Stock (VSTM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Verastem on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Verastem Shares that will get you 0.1623 shares as per Verastem share price of $9.24 per share as on September 2, 2025 at 11:42 pm IST.

What is the minimum amount required to buy Verastem Stock (VSTM) from India?

Indian investors can start investing in Verastem (VSTM) shares with as little as ₹88.148 or $1 (as of September 02, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.48 in Verastem stock (as per the Rupee-Dollar exchange rate as on September 02, 2025). Based on Verastem share’s latest price of $9.24 as on September 2, 2025 at 11:42 pm IST, you will get 1.0823 shares of Verastem. Learn more about fractional shares .

What are the returns that Verastem has given to Indian investors in the last 5 years?

Verastem stock has given 690.6% share price returns and 20.75% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?